Allon starts recruitment in AL-208 phase 2 cognitive impairment trial

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Allon Therapeutics, Inc. said Health Canada will allow the company to begin recruiting Canadian patients into an ongoing phase 2 clinical trial evaluating its product AL-208 as a treatment for the mild cognitive impairment that commonly occurs following coronary artery bypass graft surgery.

The trial is currently evaluating the safety and effectiveness of AL-208 at preventing or reducing mild cognitive impairment in coronary artery bypass graft surgery patients at several clinical sites in the United States.

Allon is a clinical-stage biotechnology company based in Vancouver.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.